



LAHIVE  
&  
COCKFIELD  
L L P

COUNSELLORS AT LAW  
28 STATE STREET  
BOSTON, MASSACHUSETTS 02109-1784  
TELEPHONE (617) 227-7400  
FAX (617) 742-4214  
lc@lahive.com

JOHN A. LAHIVE, JR. (1928-1997)  
THOMAS V. SMURZYNSKI  
RALPH A. LOREN  
GIULIO A. DECONTI, JR.  
ANN LAMPORT HAMMITTE  
ELIZABETH A. HANLEY  
AMY BAKER MANDRAGOURAS  
ANTHONY A. LAURENTANO  
KEVIN J. CANNING  
JANE E. REMILLARD  
DEANN FORAN SMITH  
PETER C. LAURO  
JEANNE M. DIGIORGIO  
DEBRA J. MILASINIC, Ph.D.  
DAVID J. RIKKERS  
DAVID R. BURNS  
JOHN S. CURRAN  
SEAN D. DETWEILER

CYNTHIA L. KANIK, Ph.D.  
MEGAN E. WILLIAMS, Ph.D.  
RICHANAND  
MICHAEL PHILLIPPS  
LISA M. DIROCCO

SENIOR COUNSEL  
JAMES E. COCKFIELD

OF COUNSEL  
JEREMIAH LYNCH  
WILLIAM A. SCOFIELD, JR.

PATENT AGENTS  
PETER S. STECHER  
THEODORE R. WEST  
SHAYNE Y. HUFF, Ph.D.  
HATHAWAY P. RUSSELL  
DANIEL B. F.O.

TECHNICAL SPECIALISTS  
MARIA LACCOTRIPE ZACHARAKIS, Ph.D. \*\*  
CYNTHIA M. SOROOS  
PETER W. DINI, Ph.D.  
EUIHOON LEE  
JENNIFER K. ROSENFELD  
ALLAN TAMESHTIT, Ph.D.  
CATHERINE E. McPHERSON  
ERIC F. WAGNER, Ph.D.  
SHAHID HASAN, Ph.D.  
JACOB G. WEINTRAUB  
JONATHAN M. SPARKS, Ph.D.  
CRISTIN E. HOWLEY, Ph.D.

\* Admitted in NY only  
\*\* Passed the Patent Bar Examination

October 12, 2001

Commissioner for Patents  
Washington, D.C. 20231

Re: U.S. Patent Application Serial No. 09/816,697  
Title: *A NOVEL P-SELECTIN GLYCOPROTEIN LIGAND (PSGL-1)  
BINDING PROTEIN AND USES THEREFOR*  
Inventors: Meike Lorenz, *et al.*  
Filed: March 23, 2001  
Attorney Docket No.: GFN-5380

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Information Disclosure Statement;
2. PTO Form 1449;
3. Copies of references cited in PTO Form 1449; and
4. A return postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

**Certificate of First Class Mailing (37 CFR 1.8(a))**

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on:

October 12, 2001

Date

Amy E. Mandragouras, Esq., Reg. No. 36,207

Respectfully submitted,

LAHIVE & COCKFIELD, LLP

Amy E. Mandragouras, Esq.  
Registration No. 36,207  
Attorney for Applicants

RECEIVED  
OCT 19 2001  
TECH CENTER 1600 2900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Meike Lorenz, *et al.*

Serial No.: 09/816,697

Filed: March 23, 2001

For: *A NOVEL P-SELECTIN GLYCOPROTEIN  
LIGAND (PSGL-1) BINDING PROTEIN AND USES  
THEREFOR*

Attorney Docket No.: GFN-5380

Group Art Unit: 1646

Examiner: Not yet assigned

22900

RECEIVED

Commissioner for Patents  
Washington, D.C. 20231


Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

October 12, 2001

Date of Signature and of Mail Deposit

By:

  
Amy E. Mandragouras, Esq.  
Registration No. 36,207  
Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT


Dear Sir:

Applicants and their attorney are aware of the following publications and information, listed on the attached PTO Form 1449, and in accordance with 37 C.F.R. §1.97 hereby submit these publications for the Examiner's consideration. A copy of each cited publication is enclosed.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 C.F.R. § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,  
LAHIVE & COCKFIELD, LLP



Amy E. Mandragouras, Esq.  
Registration No. 36,207  
Attorney for Applicants

28 State Street  
Boston, MA 02109  
(617) 227-7400

Date: October 12, 2001

AEM/LMD/alf  
Enclosures